Lugano, Switzerland, 19 September 2021 – Adding a CDK 4/6 inhibitor to first-line hormonal remedy prolongs survival by one yr for postmenopausal ladies with hormone receptor (HR) constructive, HER2 detrimental superior breast most cancers, in keeping with late breaking outcomes of the MONALEESA-2 trial introduced on the ESMO Congress 2021. (1)
Credit: ESMO
Lugano, Switzerland, 19 September 2021 – Adding a CDK 4/6 inhibitor to first-line hormonal remedy prolongs survival by one yr for postmenopausal ladies with hormone receptor (HR) constructive, HER2 detrimental superior breast most cancers, in keeping with late breaking outcomes of the MONALEESA-2 trial introduced on the ESMO Congress 2021. (1)
This is the primary report of a statistically important and clinically significant general survival profit on this affected person inhabitants.
Study writer Prof. Gabriel N. Hortobagyi, Professor of Medicine, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, US mentioned: “Previous studies have shown that CDK 4/6 inhibitors in combination with standard hormonal treatment prolong the duration of disease control, also called progression-free survival (PFS), by approximately one year. These drugs were subsequently approved by the regulatory agencies and have been available for patients with HR positive, HER2 negative advanced breast cancer. Today’s results add to this by showing that the CDK 4/6 inhibitor ribociclib extends survival by one year.”
The trial randomly allotted 668 sufferers to ribociclib plus the aromatase inhibitor letrozole or placebo plus letrozole. Patients have been excluded if that they had beforehand obtained a CDK 4/6 inhibitor, chemotherapy or endocrine remedy within the superior setting. As already reported, the median PFS was 25.3 months for ribociclib plus letrozole and 16.0 months for placebo plus letrozole. (2) Overall survival was evaluated after 400 deaths and confirmed a median length of 63.9 months for ribociclib plus letrozole in contrast with 51.4 months for placebo plus letrozole.
Hortobagyi commented: “To put these results into perspective, in my 45 years as an oncologist there have been tens of thousands of clinical trials for breast cancer and while a PFS benefit has been shown many, many times, we have rarely observed an improvement in overall survival. It is difficult to show a statistically significant extension in survival for first-line therapy in this type of breast cancer because due to the development of resistance, patients receive four to 15 different types of treatment over the course of their disease and these dilute the effect of the first therapy.”
Commenting on the findings, Prof. Giuseppe Curigliano, Clinical Director, Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, Milan, Italy pointed out: “It is important to note that these data are related to endocrine-sensitive patients who had not previously received endocrine therapy for metastatic disease. The clinical implication is that now we have a clear demonstration that the combination of endocrine therapy plus the CDK 4/6 inhibitor ribociclib prolongs both progression-free survival and overall survival.”
“My advice would be to compare the exceptional responders and long-term survivors with the exceptional progressors and short-term survivors,” Curigliano mentioned, hinting on the want for additional analysis: “This could identify biological features that may predict which patients benefit the most from this therapy. If a mechanism of resistance is found, then research could be conducted to develop new therapies for the non-responders.”
Hortobagyi famous that analysis is ongoing to look at whether or not there are any subgroups within the research that benefitted kind of from remedy. “We are also looking for biomarkers, meaning proteins or other substances that could be tested to tell the physician which patients are likely to respond to therapy and which patients are unlikely to respond,” he mentioned. “Those are very important decisions because these drugs are enormously expensive and while they are well tolerated, they do produce some side-effects and toxicities.”
He added that the findings could be generalised to sufferers with such a most cancers around the globe: “This trial included patients from 29 countries in Western Europe, the Americas and East Asia and the results can be extrapolated to HR positive, HER2 negative metastatic breast cancer regardless of their ethnicity.”
Hortobagyi concluded: “While this is the only CDK 4/6 inhibitor to demonstrate an overall survival benefit in this patient population so far, we are still waiting for results of the palbociclib and abemaciclib trials. And of course there are other emerging treatments such as other kinase inhibitors so there is more research to come in this field.”
-END-
Notes to Editors
Please ensure to make use of the official title of the assembly in your reviews: ESMO Congress 2021
Official Congress Hashtag: #ESMO21
Disclaimer
This press launch incorporates data offered by the writer of the highlighted summary and displays the content material of this summary. It doesn’t essentially mirror the views or opinions of ESMO who can’t be held liable for the accuracy of the info. Commentators quoted within the press launch are required to adjust to the ESMO Declaration of Interests coverage and the ESMO Code of Conduct.
References
1 LBA17_PR ‘Overall survival (OS) outcomes from the phase III MONALEESA-2 (ML-2) trial of postmenopausal sufferers (pts) with hormone receptor constructive/human epidermal progress issue receptor 2 detrimental (HR+/HER2−) superior breast most cancers (ABC) handled with endocrine remedy (ET) ± ribociclib (RIB)‘ will be introduced by Gabriel N. Hortobagyi throughout the Proffered Paper session – Breast most cancers, metastatic on Sunday, 19 September, 13:30 to 14:55 (CEST) on Channel 1. Annals of Oncology, Volume 32, 2021 Supplement 5
2 Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated outcomes from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative superior breast most cancers. Ann Oncol. 2018;29:1541–1547.
About the European Society for Medical Oncology (ESMO)
ESMO is the main skilled organisation for medical oncology. With greater than 25,000 members representing oncology professionals from over 160 international locations worldwide, ESMO is the society of reference for oncology schooling and data. Driven by a shared dedication to safe the very best outcomes for sufferers, ESMO is dedicated to standing by those that care about most cancers via addressing the various wants of #ONEoncologycommunity, providing #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
LBA17_PR – Overall survival (OS) outcomes from the phase III MONALEESA-2 (ML-2) trial of postmenopausal sufferers (pts) with hormone receptor constructive/human epidermal progress issue receptor 2 detrimental (HR+/HER2−) superior breast most cancers (ABC) handled with endocrine remedy (ET) ± ribociclib (RIB)
G.N. Hortobagyi1, S.M. Stemmer2, H.A. Burris III3, Y.S. Yap4, G.S. Sonke5, L. Hart6, M. Campone7, Ok. Petrakova8, E.P. Winer9, W. Janni10, P.F. Conte11, D. Cameron12, F. André13, C. Arteaga14, J.P. Zarate15, A. Chakravartty15, T. Taran16, F. Le Gac16, P. Serra16, J. O’Shaughnessy17
1Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America, 2Department Of Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Tel Aviv, Israel, 3Oncology, Sarah Cannon Research Institute, Nashville, United States of America, 4Medical Oncology, NCCS – National Cancer Centre Singapore, Singapore, 5Medical Oncology, NKI-AVL – Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, 6Oncology, Florida Cancer Specialists, Sarah Cannon Research Institute, Ft. Myers, United States of America, 7Institut de Cancérologie de l’Ouest, René Gauducheau, St Herblain, France, 8Masarykův Onkologický Ustav, Brno, Czech Republic, 9Medicine, Dana Farber Cancer Institute, Boston, United States of America, 10Frauenklinik, Ulm Medical University, Ulm, Germany, 11Surgery, Oncology And Gastroenterology, University of Padova, Padova, Italy, 12Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom, 13Medical Oncology, Gustave Roussy, Villejuif, France, 14Hematology/oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, United States of America, 15Oncology, Novartis Pharmaceuticals Corporation, East Hanover, United States of America, 16Oncology Global Development Unit, Novartis Pharma AG, Basel, Switzerland, 17Medical Oncology, Texas Oncology – Baylor Sammons Cancer Center, Dallas, United States of America
Background: ML-2 (NCT01958021) is a randomized phase III medical trial investigating first-line (1L) RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), + letrozole (LET) vs placebo (PBO) + LET in postmenopausal pts with HR+/HER2− ABC. ML-2 beforehand reported a statistically important enchancment in progression-free survival (PFS; major endpoint) with RIB + LET vs PBO + LET (HR, 0.56; 95% CI, 0.43-0.72). We report the protocol-specified closing evaluation of OS (key secondary endpoint).
Methods: Postmenopausal pts with HR+/HER2− ABC have been randomized 1:1 to obtain RIB + LET or PBO + LET. Pts have been excluded in the event that they obtained a previous CDK4/6i, chemotherapy (CT), or ET within the superior setting. OS was evaluated with a stratified log-rank check and summarized utilizing Kaplan–Meier strategies. This protocol-specified evaluation was deliberate after 400 deaths.
Results: The intention-to-treat inhabitants included 668 pts (RIB: 334; PBO: 334). At information cutoff (10 June 2021), 47 pts have been nonetheless on remedy (RIB: 30 [9.0%]; PBO: 17 [5.1%]) and the median follow-up was 79.7 mo (min, 74.6 mo). Final OS was evaluated after 400 deaths (RIB: 181 [54.2%]; PBO: 219 [65.6%]). RIB + LET confirmed a major OS profit vs PBO + LET (median, 63.9 vs 51.4 mo; HR, 0.76; 95% CI, 0.63-0.93; P=.004) and met the boundary of statistical significance. Estimated 6-year OS charge was 44.2% for RIB vs 32.0% for PBO. Time to first CT (median, 50.6 vs 38.9 mo; HR, 0.74; 95% CI, 0.61-0.91) and CT-free survival (median, 39.9 vs 30.1 mo; HR, 0.74; 95% CI, 0.62-0.89) confirmed a constant profit for RIB vs PBO. Among pts who discontinued research remedy, 87.8% vs 90.2% obtained a subsequent antineoplastic remedy for RIB vs PBO, respectively, and 21.7% and 34.4% obtained a subsequent CDK4/6i. No new security alerts have been noticed.
Conclusions: To date, that is the primary report of a statistically important and clinically significant OS profit with a 1L CDK4/6i in postmenopausal pts with HR+/HER2– ABC. After a median follow-up of >6.5 y, median OS enchancment was >12 mo for 1L RIB + LET vs PBO + LET.
Clinical trial identification: NCT01958021 (CLEE011A2301)
Editorial acknowledgement: This summary was developed with editorial help offered by Casey Nielsen, PhD of MediTech Media, LLC. Editorial help was funded by Novartis Pharmaceuticals Corporation.
Legal entity liable for the research: Novartis Pharmaceuticals Corporation
Funding: Pharmaceutical, biotech, or different industrial firm – Novartis Pharmaceuticals Corporation
|
Disclosure: |
G.N. Hortobagyi: Financial Interests, Personal, Research Grant, Grant help to establishment to conduct trial. Personal charges member/chair Steering Committee: Novartis. S.M. Stemmer: Financial Interests, Institutional, Research Grant: Rabin Medical Center. H.A. Burris III: Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Novartis; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Astra Zeneca; Financial Interests, Institutional, Other, Payment to establishment for consulting companies carried out by Dr. Burris: Astra Zeneca; Financial Interests, Institutional, Other, Payment to establishment for consulting companies carried out by Dr. Burris: FORMA Therapeutics ; Financial Interests, Institutional, Other, Payment to establishment for consulting companies carried out by Dr. Burris: Celgene; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Incyte; Financial Interests, Institutional, Other, ayment to establishment for consulting companies carried out by Dr. Burris: Incyte; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Roche; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Bristol-Myers Squibb; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : MedImmune; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Macrogenics; Financial Interests, Institutional, Other, Payment to establishment for knowledgeable testimony carried out by Dr. Burris : Novartis; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Boehringer Ingelheim; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Lilly; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Seattle Genetics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Merck; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Aglos; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Jounce Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Moderna Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : CytomX Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : GlaxoSmithKline; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Verastem; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Tesaro; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : BioMed Valley Discoveries; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : TG Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Vertex; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : eFFECTOR Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Janssen; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Gilead Sciences; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : BioAtla; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : CicloMed; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Harpoon Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Arch; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Arvinas; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Revolution Medicines; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Array BioPharma; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Bayer; Non-Financial Interests, Personal, Other, Non-compensated consulting companies carried out by Dr. Burris : Bayer, Pfizer, Novartis; Financial Interests, Institutional, Invited Speaker, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : BIND Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Kyocera; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : miRNA Therapeutics; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Pfizer; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Takeda/Millennium; Financial Interests, Institutional, Principal Investigator, Payment to establishment for conduct of medical trial in which Dr. Burris served as PI. : Foundation Medicine; Non-Financial Interests, Personal, Other, Uncompensated consulting work: Daiichi Sankyo; Financial Interests, Personal and Institutional, Full or part-time Employment: HCA Healthcare/Sarah Cannon; Financial Interests, Personal and Institutional, Leadership Role: HCA Healthcare/Sarah Cannon; Financial Interests, Personal and Institutional, Stocks/Shares: HCA Healthcare/Sarah Cannon; Non-Financial Interests, Personal, Other, Non-compensated consulting companies carried out by Dr. Burris : GRAIL. Y.S. Yap: Financial Interests, Personal, Other, not specified: Novartis; Non-Financial Interests, Personal, Other, not specified: Novartis; Financial Interests, Personal, Other, not specified: Pfizer; Non-Financial Interests, Personal, Other, not specified: Pfizer; Financial Interests, Personal, Other, not specified: Lilly; Non-Financial Interests, Personal, Other, not specified: Lilly; Financial Interests, Personal, Other, not specified: Astra Zeneca; Non-Financial Interests, Personal, Other, not specified: Astra Zeneca; Financial Interests, Personal, Other, not specified: Roche; Non-Financial Interests, Personal, Other, not specified: Roche; Financial Interests, Personal, Other, not specified: Eisai; Non-Financial Interests, Personal, Other, not specified: Eisai; Financial Interests, Personal, Other, not specified: MSD; Financial Interests, Personal, Other, not specified: Inivata. G.S. Sonke: Financial Interests, Institutional, Other, Institutional reimbursement for affected person accrual: Novartis; Financial Interests, Institutional, Other, Institutional reimbursement for schooling and steering committee actions: Novartis; Non-Financial Interests, Institutional, Other, Institutional analysis help: Merck; Non-Financial Interests, Institutional, Other, Institutional analysis help: Astra Zeneca; Non-Financial Interests, Institutional, Other, Institutional analysis help: Roche. L. Hart: Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Personal, Speaker’s Bureau: Novartis. M. Campone: Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Astra Zeneca; Financial Interests, Personal, Advisory Board: Eli Lilly. Ok. Petrakova: Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Astra Zeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: BMS. E.P. Winer: Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Tessaro; Financial Interests, Personal, Advisory Board: Leap; Financial Interests, Institutional, Research Grant, Research funding (establishment): Merck; Financial Interests, Institutional, Research Grant, Research funding (establishment): Genentech. W. Janni: Financial Interests, Personal and Institutional, Research Grant: Novartis. P.F. Conte: Financial Interests, Personal, Writing Engagements: Novartis. D. Cameron: Financial Interests, Institutional, Advisory Board, Institution reimbursed for my time on advisory boards: Novartis; Financial Interests, Institutional, Advisory Board, Institution reimbursed for my time on advisory boards: Pfizer; Financial Interests, Institutional, Other, Institution reimbursed for my time on an IDMC: Lilly. F. André: Financial Interests, Institutional, Funding, Research funding (establishment): Astra Zeneca; Financial Interests, Institutional, Funding, Research funding (establishment): Lilly; Financial Interests, Institutional, Funding, Research funding (establishment): Novartis; Financial Interests, Institutional, Funding, Research funding (establishment): Pfizer; Financial Interests, Institutional, Funding, Research funding (establishment): Roche. C. Arteaga: Financial Interests, Institutional, Research Grant, Research funding : Pfizer; Financial Interests, Institutional, Research Grant, Research funding : Lilly; Financial Interests, Institutional, Research Grant, Research funding : Takeda; Financial Interests, Institutional, Research Grant, Research funding : Radius; Financial Interests, Institutional, Research Grant, Research funding : PUMA Technology; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Symphogen; Financial Interests, Personal, Advisory Board: TAIHO Oncology; Financial Interests, Personal, Advisory Board: PUMA Technology; Financial Interests, Personal, Advisory Board: RADIUS; Financial Interests, Personal, Advisory Board: H3Biomedicine; Financial Interests, Personal, Advisory Board: OrigiMed; Financial Interests, Personal, Advisory Board: Daiichi Sankyo. J.P. Zarate: Financial Interests, Personal and Institutional, Full or part-time Employment: Novartis; Financial Interests, Personal and Institutional, Stocks/Shares: Novartis. A. Chakravartty: Financial Interests, Personal and Institutional, Full or part-time Employment: Novartis; Financial Interests, Personal and Institutional, Stocks/Shares: Novartis. T. Taran: Financial Interests, Personal and Institutional, Full or part-time Employment: Novartis; Financial Interests, Personal and Institutional, Stocks/Shares: Novartis. F. Le Gac: Financial Interests, Personal and Institutional, Full or part-time Employment: Novartis; Financial Interests, Personal and Institutional, Stocks/Shares: Novartis. P. Serra: Financial Interests, Personal and Institutional, Full or part-time Employment: Novartis; Financial Interests, Personal and Institutional, Stocks/Shares: Novartis. J. O’Shaughnessy: Financial Interests, Personal, Advisory Board, Consultant/Advisory Board: Astra Zeneca; Financial Interests, Personal, Advisory Board, Consultant/Advisory Board: Novartis; Financial Interests, Personal, Advisory Board, Consultant/Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board, Consultant/Advisory Board: Lilly; Financial Interests, Personal, Advisory Board, Consultant/Advisory Board: Merck; Financial Interests, Personal, Advisory Board, Consultant/Advisory Board: Seattle Genetics. |
Journal
Annals of Oncology
